24,707 reports of this reaction
1.7% of all ADALIMUMAB reports
#11 most reported adverse reaction
PSORIASIS is the #11 most commonly reported adverse reaction for ADALIMUMAB, manufactured by AbbVie Inc.. There are 24,707 FDA adverse event reports linking ADALIMUMAB to PSORIASIS. This represents approximately 1.7% of all 1,482,766 adverse event reports for this drug.
Patients taking ADALIMUMAB who experience psoriasis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PSORIASIS is a less commonly reported adverse event for ADALIMUMAB, but still significant enough to appear in the safety profile.
In addition to psoriasis, the following adverse reactions have been reported for ADALIMUMAB:
The following drugs have also been linked to psoriasis in FDA adverse event reports:
PSORIASIS has been reported as an adverse event in 24,707 FDA reports for ADALIMUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
PSORIASIS accounts for approximately 1.7% of all adverse event reports for ADALIMUMAB, making it a notable side effect.
If you experience psoriasis while taking ADALIMUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.